Materials and methods
NLFs (0.5 ml on each side), allergic
SKIN CANCERS, CONNECTIVE TISSUE DISORDER
This prospective, single-center, evaluator-blinded pilot study enrolled 60 Thai female adult patients. The women had expressed dissatisfaction with their NLFs, scoring − 1 or − 2 on the Subject Wrinkle Assessment Scale (Table were pregnant or lactatinghad a history of connective tissue disorder, skin cancers, or related diseaseshad previous autologous fibroblast treatmenthad treatment with fillers, lasers, or energy-based devices during the previous 12 monthshad treatment using transdermal drug delivery, chemical peeling, or topical retinoid during the previous monthwere allergic to collagen, meat, dairy products, gentamycin, amphotericin B, or related productsSubject Wrinkle Assessment ScaleEvaluator Wrinkle Severity Assessment ScaleThe subjects were randomly divided following simple randomization procedures into 2 groups (“HA filler” and “autologous fibroblast”). The HA filler group was given a single injection of HA filler (Restylane; Q-Med AB, Uppsala, Sweden) on both NLFs (0.5 ml on each side) by using 22-guage cannula. The autologous fibroblast group was intradermally injected with autologous cultured fibroblasts on both NLFs (0.5 ml on each side) by using 30-guage needle. However, the fibroblast injections were administered in 3 sessions at 2-week intervals.